Alpha-2C adrenergic receptor (ADRA2C) (ADRA2C)

The Alpha-2C adrenergic receptor (ADRA2C) is a G protein-coupled receptor (GPCR) belonging to the alpha-2 adrenergic subfamily [1, 2]. It is primarily localized in the central nervous system, including the basal ganglia, hippocampus, and cerebral cortex, and is also found in peripheral tissues such as vascular smooth muscle [5, 10]. ADRA2C functions as a presynaptic autoreceptor that inhibits the release of norepinephrine and other neurotransmitters, particularly during low levels of nerve activity [1, 5, 6]. This regulatory mechanism is essential for fine-tuning sympathetic tone, cardiovascular function, and cognitive processes [1, 4, 7]. Dysregulation of ADRA2C is associated with various conditions, including Raynaud's phenomenon, heart failure, and psychiatric disorders like schizophrenia and ADHD [4, 8, 13]. Pharmacologically, the receptor is targeted by agonists such as dexmedetomidine for its sedative and analgesic properties, while selective antagonists like ORM-12741 are being explored for cognitive enhancement and cardiovascular benefits [7, 9, 10]. The receptor's unique intracellular trafficking and potential for heterodimerization with other GPCRs, such as the beta-2 adrenergic receptor, influence its surface expression and functional signaling [14, 15].

Other names

Alpha-2C adrenoceptorAlpha-2C adrenoreceptorADRA2L2ADRA2RL2ADRARL2Alpha-2 adrenergic receptor subtype C4ALPHA2CAR

Agonists bind to the receptor, activating Gi/o proteins which inhibit adenylate cyclase, leading to decreased intracellular cAMP levels, stimulation of ERK1/2, and suppression of voltage-gated calcium channels [1, 4, 6]. This results in the inhibition of neurotransmitter release (e.g., norepinephrine) from presynaptic terminals [1, 5, 6]. Antagonists block these inhibitory effects, thereby increasing neurotransmitter release and modulating sympathetic and central nervous system activity [7].